Horizon Therapeutics Public Limited Company (HZNP) has a consensus analyst rating of Buy, based on 25 analysts covering the stock. Of those, 15 recommend buying, 10 recommend holding, and 0 recommend selling.
The analyst consensus price target for HZNP is $127.15, representing a +9.3% upside from the current price of $116.3. Price targets range from a low of $110.00 to a high of $144.00.
